Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1989 4
1990 8
1991 6
1992 8
1993 4
1994 10
1995 4
1996 7
1997 5
1998 6
1999 6
2000 5
2001 7
2002 8
2003 6
2004 4
2005 3
2006 2
2007 4
2008 7
2009 4
2010 1
2012 1
2014 1
2015 1
2017 1
2021 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Results by year

Filters applied: . Clear all
Page 1
Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application.
Kieback AG, Felix SB, Reffelmann T. Kieback AG, et al. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1337-47. doi: 10.1517/17425250903282773. Expert Opin Drug Metab Toxicol. 2009. PMID: 19761414 Review.
Quinaprilat is excreted mainly in urine. In long-term animal studies, quinaprilat was not teratogenic, mutagenic or carcinogenic. ...CONCLUSION: Quinaprilat is an attractive ACE inhibitor, which potently inhibits tissue ACE....
Quinaprilat is excreted mainly in urine. In long-term animal studies, quinaprilat was not teratogenic, mutagenic or carcinogen …
Quinaprilat induces arterial vasodilation mediated by nitric oxide in humans.
Haefeli WE, Linder L, Lüscher TF. Haefeli WE, et al. Hypertension. 1997 Oct;30(4):912-7. doi: 10.1161/01.hyp.30.4.912. Hypertension. 1997. PMID: 9336392
In particular, recently developed ACE inhibitors with tissue-penetrating properties, such as quinaprilat, may exert vascular effects via the bradykinin B2-receptor. To test direct arterial effects of quinaprilat and enalaprilat and to study their effects on vasodila …
In particular, recently developed ACE inhibitors with tissue-penetrating properties, such as quinaprilat, may exert vascular effects …
Quinaprilat during cardioplegic arrest in the rabbit to prevent ischemia-reperfusion injury.
Korn P, Kröner A, Schirnhofer J, Hallström S, Bernecker O, Mallinger R, Franz M, Gasser H, Wolner E, Podesser BK. Korn P, et al. J Thorac Cardiovasc Surg. 2002 Aug;124(2):352-60. doi: 10.1067/mtc.2002.121676. J Thorac Cardiovasc Surg. 2002. PMID: 12167796 Free article. Clinical Trial.
RESULTS: All treatments substantially improved postischemic recovery of external heart work (62% +/- 6%, 69% +/- 3%, and 64% +/- 5% in quinaprilat during cardioplegia, quinaprilat during reperfusion, and l-arginine groups, respectively, vs 35% +/- 5% in control grou …
RESULTS: All treatments substantially improved postischemic recovery of external heart work (62% +/- 6%, 69% +/- 3%, and 64% +/- 5% in qu …
The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment.
Begg EJ, Robson RA, Bailey RR, Lynn KL, Frank GJ, Olson SC. Begg EJ, et al. Br J Clin Pharmacol. 1990 Aug;30(2):213-20. doi: 10.1111/j.1365-2125.1990.tb03767.x. Br J Clin Pharmacol. 1990. PMID: 2144994 Free PMC article.
The apparent oral plasma clearance of quinaprilat (dose of quinapril equivalent/AUC of quinaprilat) was directly related to creatinine clearance (CLCr). The predicted apparent oral clearance of quinaprilat was zero when CLCr was zero, suggesting minimal extra …
The apparent oral plasma clearance of quinaprilat (dose of quinapril equivalent/AUC of quinaprilat) was directly related to cr …
Quinaprilat reduces myocardial infarct size involving nitric oxide production and mitochondrial KATP channel in rabbits.
Chen X, Minatoguchi S, Wang N, Arai M, Lu C, Uno Y, Misao Y, Takemura G, Fujiwara H. Chen X, et al. J Cardiovasc Pharmacol. 2003 Jun;41(6):938-45. doi: 10.1097/00005344-200306000-00017. J Cardiovasc Pharmacol. 2003. PMID: 12775974
Quinaprilat did not affect the myocardial interstitial 2,5-DHBA level but significantly increased the NOx level during ischemia and reperfusion. Quinaprilat reduces myocardial infarct size involving NO production and mitochondrial KATP channels in rabbits without co …
Quinaprilat did not affect the myocardial interstitial 2,5-DHBA level but significantly increased the NOx level during ischemia and r …
A pharmacodynamic and pharmacokinetic comparison of intravenous quinaprilat and oral quinapril.
Breslin E, Posvar E, Neub M, Trenk D, Jahnchen E. Breslin E, et al. J Clin Pharmacol. 1996 May;36(5):414-21. doi: 10.1002/j.1552-4604.1996.tb05028.x. J Clin Pharmacol. 1996. PMID: 8739020 Clinical Trial.
The magnitude of effect was similar after administration of 20 mg quinapril orally and 10 mg quinaprilat intravenously. Duration of action was longer, however, after administration of intravenous quinaprilat (10 mg) than after oral quinapril (20 mg), due to the high …
The magnitude of effect was similar after administration of 20 mg quinapril orally and 10 mg quinaprilat intravenously. Duration of a …
Effects of quinapril on angiotensin converting enzyme and plasma renin activity as well as pharmacokinetic parameters of quinapril and its active metabolite, quinaprilat, after intravenous and oral administration to mature horses.
Davis JL, Kruger K, LaFevers DH, Barlow BM, Schirmer JM, Breuhaus BA. Davis JL, et al. Equine Vet J. 2014 Nov;46(6):729-33. doi: 10.1111/evj.12206. Epub 2014 Jan 7. Equine Vet J. 2014. PMID: 24175935 Clinical Trial.
Blood was collected for measurement of quinapril and quinaprilat concentrations using ultra-high pressure liquid chromatography with mass spectrometry. ...Maximum concentration for quinaprilat was 145 ng/ml at 0.167 h. Bioavailability of quinapril following oral adm …
Blood was collected for measurement of quinapril and quinaprilat concentrations using ultra-high pressure liquid chromatography with …
Protective effects of quinaprilat and trandolaprilat, active metabolites of quinapril and trandolapril, on hemolysis induced by lysophosphatidylcholine in human erythrocytes.
Hayase N, Satomi M, Hara A, Awaya T, Shimizu K, Matsubara K. Hayase N, et al. Biol Pharm Bull. 2003 May;26(5):712-6. doi: 10.1248/bpb.26.712. Biol Pharm Bull. 2003. PMID: 12736518 Free article.
Since propranolol possesses a membrane stabilizing action correlated with high lipophilicity, it appears that the high lipophilicity of quinaprilat or trandolaprilat is responsible for the protection from the damage induced by LPC. ...Furthermore, neither propranolol (100 …
Since propranolol possesses a membrane stabilizing action correlated with high lipophilicity, it appears that the high lipophilicity of q …
Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis.
Yamada S, Muraoka I, Kato K, Hiromi Y, Takasu R, Seno H, Kawahara H, Nabeshima T. Yamada S, et al. Biol Pharm Bull. 2003 Jun;26(6):872-5. doi: 10.1248/bpb.26.872. Biol Pharm Bull. 2003. PMID: 12808303 Free article. Clinical Trial.
Plasma concentrations of quinaprilat and perindoprilat were measured by high-performance liquid chromatography (HPLC) and radioimmunoassay, respectively. ...Values of haemodialysis clearance (CL(HD)) and extraction ratio (ER) were 51.5+/-30.2 ml/min and 0.35+/-0.21 for …
Plasma concentrations of quinaprilat and perindoprilat were measured by high-performance liquid chromatography (HPLC) and radioimmuno …
Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure.
Hornig B, Arakawa N, Haussmann D, Drexler H. Hornig B, et al. Circulation. 1998 Dec 22-29;98(25):2842-8. doi: 10.1161/01.cir.98.25.2842. Circulation. 1998. PMID: 9860785 Clinical Trial.
Quinaprilat improved FDD by >40% (10.2+/-0.6% versus 6.9+/-0.6%; P<0.01), whereas enalaprilat had no effect. ...The effect of sodium nitroprusside on radial artery diameter and blood flow was similar in patients treated with quinaprilat, enalaprilat, and place …
Quinaprilat improved FDD by >40% (10.2+/-0.6% versus 6.9+/-0.6%; P<0.01), whereas enalaprilat had no effect. ...The effect of s …
123 results